Analysts at StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) in a research report issued on Friday. The brokerage set a “sell” rating on the stock.
Ayala Pharmaceuticals Price Performance
Shares of NASDAQ:ADXS opened at $0.21 on Friday. Ayala Pharmaceuticals has a 1-year low of $0.13 and a 1-year high of $1.95. The company has a market capitalization of $8.78 million, a P/E ratio of -0.03 and a beta of 1.55. The firm’s 50 day simple moving average is $0.32 and its two-hundred day simple moving average is $0.56.
Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) last issued its quarterly earnings results on Tuesday, April 16th. The company reported ($2.96) earnings per share for the quarter.
Ayala Pharmaceuticals Company Profile
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
Further Reading
- Five stocks we like better than Ayala Pharmaceuticals
- Comparing and Trading High PE Ratio Stocks
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.